Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
L. Qin, J. Xu, J. Chen…·H. Liu
The paper identifies galectin-9 and AG-specific antibodies that inhibit Mtb growth by targeting arabinogalactan, offering a new immunotherapeutic strategy for TB.
N. D. Vincelette, X. Yu, A. T. Kuykendall…·S. Yun
This study identifies a MYC-S100A9 axis driving triple negative myelofibrosis and shows it is a therapeutic target.
R. M. Hurley, C. D. McGehee, K. Nesic…·S. H. Kaufmann
This study shows that PARPi treatment can reverse RAD51C promoter methylation and restore expression in a high-grade serous ovarian cancer model, while maintaining platinum sensitivity.
K. Nesic, O. Kondrashova, R. M. Hurley…·C. L. Scott
This study shows that loss of RAD51C promoter methylation leads to PARP inhibitor resistance in high-grade serous ovarian carcinoma, independent of BRCA1 methylation status.
R. M. Carr, D. Vorobyev, T. Lasho…·M. M. Patnaik
This study identifies RAS mutations as drivers of proliferative CMML through a novel KMT2A-PLK1 axis, showing PLK1 inhibition can improve disease outcomes in patient-derived xenografts.